ophthalmic solution

A new drug application (NDA) for VYZULTA — a prostaglandin analogue indicated for the reduction of intraocular pressure (IOP) — has been approved by the US Food and Drug Administration (FDA). Read more


Ophthalmic Squeeze Dispenser

Courtesy of Allergan

Aptar Pharma’s innovative and patented preservative-free multidose Ophthalmic Squeeze Dispenser is now available for the first time for patients in the US prescription market using Allergan’s Restasis MultiDose 0.05%. Read more


Regulatory affairs services provider ELC Group is expanding into the pharmaceutical development market with the creation of an extensive product portfolio targeting a range of therapeutic areas. Read more


Novozymes Biopharma, part of Novozymes A/S, announced that an ophthalmic solution made using its recombinant human albumin has been approved for Phase I/II development by the FDA. Read more